Monovo (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, altering gene expression to suppress the production of inflammatory cytokines and inhibit the migration of immune cells. This results in a potent anti‑inflammatory and immunosuppressive effect on the applied area.

The appropriate dose of Monovo is determined by the prescribing healthcare professional based on the severity of the skin condition, the area to be treated, and patient‑specific factors. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety data for mometasone furoate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Monovo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Monovo (mometasone furoate) is a high‑potency topical corticosteroid, offering stronger anti‑inflammatory action than low‑potency agents such as hydrocortisone. Compared with other high‑potency steroids like clobetasol, it may have a slightly lower risk of skin atrophy while providing comparable efficacy for many dermatologic conditions.

Monovo should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Monovo is applied topically to the affected skin area in a thin layer, usually once or twice daily as directed by the prescriber. The skin should be clean and dry before application, and hands should be washed after use to avoid accidental spread.

Serious risks include skin atrophy (thinning), hypopigmentation, secondary infections, and systemic effects such as adrenal suppression when large surface areas are treated for prolonged periods. Patients should report any unusual skin changes or systemic symptoms to their healthcare provider promptly.

Monovo should not be used by individuals with known hypersensitivity to mometasone furoate or any excipients in the formulation. It is also contraindicated on infected, ulcerated, or broken skin, and should be avoided in patients where systemic corticosteroid exposure is undesirable unless specifically directed by a physician.